Icure Pharmaceutical Incorporation (KOSDAQ: 175250)
South Korea
· Delayed Price · Currency is KRW 1,953.00
-57.00 (-2.84%)
Dec 20, 2024, 9:00 AM KST
Icure Pharmaceutical Incorporation Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Other Revenue | -0 | -0 | - | 0 | - | - | Upgrade
|
| Revenue | 60,610 | 56,806 | 59,367 | 64,283 | 90,144 | 60,922 | Upgrade
|
| Revenue Growth (YoY) | 1.74% | -4.31% | -7.65% | -28.69% | 47.97% | 82.84% | Upgrade
|
| Cost of Revenue | 56,163 | 55,508 | 64,947 | 69,086 | 72,165 | 42,874 | Upgrade
|
| Gross Profit | 4,447 | 1,298 | -5,580 | -4,804 | 17,979 | 18,048 | Upgrade
|
| Selling, General & Admin | 18,304 | 15,234 | 11,826 | 16,425 | 26,883 | 21,039 | Upgrade
|
| Research & Development | 2,987 | 3,685 | 4,242 | 2,419 | 3,046 | 1,685 | Upgrade
|
| Other Operating Expenses | 477.65 | 486.93 | 522.68 | 394.27 | 507.27 | 466.93 | Upgrade
|
| Operating Expenses | 31,087 | 29,023 | 21,507 | 25,316 | 33,513 | 24,424 | Upgrade
|
| Operating Income | -26,640 | -27,725 | -27,087 | -30,119 | -15,534 | -6,376 | Upgrade
|
| Interest Expense | -5,707 | -5,689 | -7,279 | -5,420 | -3,065 | -2,816 | Upgrade
|
| Interest & Investment Income | - | 785.09 | 1,309 | 949.41 | 881.81 | 1,525 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | 5,787 | 910.24 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.05 | 36.21 | -6.69 | 98.32 | -20.4 | 7.36 | Upgrade
|
| Other Non Operating Income (Expenses) | 2,419 | 1,587 | -4,377 | 2,214 | -188.19 | -2,325 | Upgrade
|
| EBT Excluding Unusual Items | -29,926 | -31,006 | -37,441 | -32,278 | -12,139 | -9,075 | Upgrade
|
| Gain (Loss) on Sale of Investments | -2,044 | 660.36 | -4,287 | -3,388 | 1,207 | 553.77 | Upgrade
|
| Gain (Loss) on Sale of Assets | 31,535 | 51.52 | -70.11 | 490.69 | -547.22 | 8.04 | Upgrade
|
| Asset Writedown | - | - | -1,292 | -3,040 | -18.29 | - | Upgrade
|
| Other Unusual Items | -130.2 | -2,231 | - | -619.46 | - | - | Upgrade
|
| Pretax Income | -565.71 | -32,525 | -43,090 | -38,835 | -11,498 | -8,513 | Upgrade
|
| Income Tax Expense | -247.61 | -226.49 | -541.28 | -450.58 | 652.62 | 141.57 | Upgrade
|
| Earnings From Continuing Operations | -318.11 | -32,299 | -42,549 | -38,384 | -12,150 | -8,654 | Upgrade
|
| Minority Interest in Earnings | 839.43 | 878.84 | 782.11 | 217.51 | -463.78 | -96.45 | Upgrade
|
| Net Income | 521.32 | -31,420 | -41,766 | -38,167 | -12,614 | -8,751 | Upgrade
|
| Net Income to Common | 521.32 | -31,420 | -41,766 | -38,167 | -12,614 | -8,751 | Upgrade
|
| Shares Outstanding (Basic) | 38 | 38 | 23 | 22 | 20 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 38 | 38 | 23 | 22 | 20 | 18 | Upgrade
|
| Shares Change (YoY) | 9.19% | 61.23% | 7.58% | 9.71% | 8.69% | 14.84% | Upgrade
|
| EPS (Basic) | 13.88 | -836.56 | -1792.96 | -1762.57 | -639.10 | -481.87 | Upgrade
|
| EPS (Diluted) | 13.88 | -837.00 | -1793.00 | -1763.00 | -639.17 | -481.94 | Upgrade
|
| Free Cash Flow | -18,365 | -15,744 | -15,479 | -31,929 | -35,399 | -68,193 | Upgrade
|
| Free Cash Flow Per Share | -488.98 | -419.20 | -664.49 | -1474.52 | -1793.49 | -3755.13 | Upgrade
|
| Gross Margin | 7.34% | 2.28% | -9.40% | -7.47% | 19.94% | 29.63% | Upgrade
|
| Operating Margin | -43.95% | -48.81% | -45.63% | -46.85% | -17.23% | -10.47% | Upgrade
|
| Profit Margin | 0.86% | -55.31% | -70.35% | -59.37% | -13.99% | -14.36% | Upgrade
|
| Free Cash Flow Margin | -30.30% | -27.72% | -26.07% | -49.67% | -39.27% | -111.93% | Upgrade
|
| EBITDA | -17,867 | -18,682 | -18,872 | -22,341 | -8,510 | -2,755 | Upgrade
|
| EBITDA Margin | -29.48% | -32.89% | -31.79% | -34.75% | -9.44% | -4.52% | Upgrade
|
| D&A For EBITDA | 8,773 | 9,043 | 8,216 | 7,778 | 7,024 | 3,621 | Upgrade
|
| EBIT | -26,640 | -27,725 | -27,087 | -30,119 | -15,534 | -6,376 | Upgrade
|
| EBIT Margin | -43.95% | -48.81% | -45.63% | -46.85% | -17.23% | -10.47% | Upgrade
|
| Advertising Expenses | - | 123.77 | 138.03 | 1,266 | 1,917 | 852.55 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.